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PainThe postictal state is generally followed by antinociception. It is known that connections between the dorsal
raphe nucleus, the periaqueductal gray matter, and the locus coeruleus, an important noradrenergic
brainstem nucleus, are involved in the descending control of ascending nociceptive pathways. The aim of the
present study was to determine whether noradrenergic mechanisms in the locus coeruleus are involved in
postictal antinociception. Yohimbine (an α2-receptor antagonist) or propranolol (a β-receptor antagonist)
was microinjected unilaterally into the locus coeruleus, followed by intraperitoneal administration of
pentylenetetrazole (PTZ), a noncompetitive antagonist that blocks GABA-mediated Cl– inﬂux. Although the
administration of both yohimbine and propranolol to the locus coeruleus/subcoeruleus area resulted in a
signiﬁcant decrease in tonic or tonic–clonic seizure-induced antinociception, the effect of yohimbine
restricted to the locus coeruleus was more distinct compared with that of propranolol, possibly because of the
presynaptic localization of α2-noradrenergic receptors in locus coeruleus neurons. These effects were related
to the modulation of noradrenergic activity in the locus coeruleus. Interestingly, microinjections of
noradrenaline into the locus coeruleus also decrease the postictal antinociception. The present results
suggest that the mechanism underlying postictal antinociception involves both α2- and β-noradrenergic
receptors in the locus coeruleus, although the action of noradrenaline on these receptors causes a paradoxical
effect, depending on the nature of the local neurotransmission.atomia & Neuropsicobiologia,
de Ribeirão Preto (FMRP) da
es, 3900, Ribeirão Preto (SP),
a).
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
γ-Aminobutyric acid (GABA)-, acetylcholine-, serotonin-, and
noradrenaline-mediated systems have often been implicated as
neuronal bases of postictal analgesia and have been the subject
of numerous studies concerning the neural basis of pain modulation
[1–10]. The periaqueductal gray matter (PAG) and certain nuclei of
the reticular formation are thought to be the main structures
involved in supraspinal pain modulation [6,10–16]. Reciprocal
connections between the locus coeruleus (LC), situated on both
sides of the median line [17], and descending pathways from the LC
are crucially involved in modulating the activity of ascending
nociceptive pathways, which, in turn, can be modulated by sero-
tonergic output from the dorsal raphe nucleus (DRN) to the dorsal
horn of the spinal cord [18,19]. These ﬁndings lead us to postulatethat the LC represents a key structure in the organization of
epilepsy-induced hypoalgesia.
Damage to noradrenaline-containing neurons in the LC converts
episodic limbic seizures induced by bicuculline infusion in the
anterior piriform cortex into self-sustaining status epilepticus [20].
Studying the roles of both α- and β-mediated LC mechanisms may
elucidate the involvement of this important noradrenergic structure
in postictal antinociception. Descending outputs from both LC and
subcoeruleus (SC) neurons are known to be involved in the
modulation of nociceptive transmission. In fact, activation of
descending LC/SC neurons can produce profound antinociception
[21,22], which may inhibit the nociceptive activity of spinal dorsal
horn neurons [23–25] and trigeminal subnucleus caudalis neurons
[17,26]. West et al. [27] suggested that both electrical stimulation of
and administration of morphine [28] into the LC have antinociceptive
effects. The interplay between the LC and serotonergic brainstem
nuclei [9,17,29] may also be important for the modulation of
nociception. It follows that stimulation of the DRN [30] and PAG
[12,31–35], both structures rich in serotonin-containing neurons and
ﬁbers [10,36,37], causes intense antinociception. In fact, α2-adreno-
ceptors and 5-HT1A somatodendritic autoreceptors have important
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serotonin and noradrenaline [38]. These autoreceptors may play key
roles in modulating neurotransmission in the LC [39,40]. In addition,
there is evidence suggesting GABAA receptor-mediated modulation of
brainstem serotonergic and noradrenergic functions, altering the
ﬁring rate of both the DRN [41] and the LC [42].
The only evidence to date for the recruitment of both α2- and β-
noradrenergic receptors in the context of postictal antinociception
was obtained from peripheral administration of speciﬁc antagonists
[9]. There is a lack of other studies suggesting the involvement of
α2- and β-noradrenergic receptors in the organization and modu-
lation of antinociceptive processes induced by brain epileptogenic
activity. In this study, we took into account previous evidence
suggesting the involvement of the LC in postictal antinociception
[9], as well as recent robust neuroanatomical ﬁndings suggesting
reciprocal connections between neurons of the LC situated on both
sides of the median line [17]. There are also several reports indi-
cating that the LC noradrenergic system plays an important role in
the descending modulation of spinothalamic ascending nociceptive
pathways [6,10,43–45]. In this context, the present study focused on
the role of presynaptic α2− and postsynaptic β-noradrenergic
receptors on LC neurons in the modulation of postictal antinocicep-
tion, to better understand the oscillation of the postseizure nocicep-
tive threshold, which is associated with the postictal immobility
syndrome.
2. Materials and methods
2.1. Animals
WeusedmaleWistar albino ratsweighing between 200 and 250 g
(n=5–9 per group) from the animal care facility of the Ribeirão Preto
Campus at the University of São Paulo (USP). The animals were
housed in groups of four in plexiglass cages and given free access to
food and water throughout the experiment. The room temperature
was controlled (22±1 °C), and a light–dark cycle (07:00–
19:00 hours lights on) was maintained. The experimental protocols
were reviewed and approved (Proc. 074/2004) by the Ethics
Commission in Animal Experimentation (CETEA) at FMRP-USP, and
all experiments were performed in accordance with the recommen-
dations of CETEA, based on the guidelines of the Brazilian Society for
Neuroscience and Behaviour (SBNeC) and on the Animal Research
Ethics standards adopted by the Brazilian College of Animal
Experimentation (COBEA).
2.2. Surgical procedures
Animals were anesthetized with sodium xilasine (0.2 mL, ip)
and ketamine (0.1 mL, ip) and ﬁxed in a stereotaxic frame (David
Kopf, USA). A stainless-steel guide cannula (o.d. 0.6 mm, i.d.
0.4 mm) was implanted unilaterally in the brainstem, aimed at
the LC. The upper incisor bar was set 3.3 mm below the interaural
line, such that the skull was horizontal between bregma and
lambda. The guide cannula was vertically introduced using the
following coordinates, with the bregma serving as the reference for
each plane: anteroposterior, –9.68 mm; mediolateral, 1.4 mm; dor-
soventral, 6 mm. The guide cannula was ﬁxed to the skull using
acrylic resin and two stainless-steel screws. At the end of the
surgery, each guide cannula was sealed with a stainless-steel wire
to prevent obstruction.
2.3. Nociceptive testing
Nociception thresholds were compared using the tail-ﬂick test.
Each animal was placed in a restraining apparatus (Stoelting) with
acrylic walls, and its tail was placed in a heating sensor (tail-ﬂickAnalgesia Instrument; Stoelting, IL, USA), the progressive calorimetric
elevation of which was automatically interrupted at the moment
when the animal removed its tail from the apparatus. The current
raised the temperature of the coil (Ni/Cr alloy; 26.04 cm in
length×0.02 cm in diameter) at a rate of 9 °C/second [46], starting
at room temperature (approximately 20 °C). If necessary, a small
current intensity adjustment was made at the start of the experiment
to obtain three consecutive tail-ﬂick latencies (TFLs) between 2.5 and
3.5 seconds. If the animal did not remove its tail from the heater
within 6 seconds, the apparatus was turned off to prevent skin
damage. As there were no statistically signiﬁcant differences between
baseline characteristics of the experimental groups, all tail-ﬂick
latencies were normalized by an index of analgesia (IA) using the
following formula:
IA =
ðTFLtestÞ− TFLcontrolð Þ
6− TFLcontrolð Þ
Three control baseline TFL readings were taken at 5-minute
intervals. TFLs were also measured following seizures elicited by the
peripheral administration of pentylenetetrazole (PTZ).
2.4. Behavioral testing and seizure evaluation
Behavioral tests were performed by placing the rats in the interior
of a circular arena with transparent acrylic walls. The arena measured
60 cm in diameter and 50 cm in height and was located in an
experimental compartment illuminated by a ﬂuorescent lamp (350 lx
at arena ﬂoor level). The effects of drug administration (PTZ,
yohimbine, propranolol, and physiological saline) were evaluated
with the rats inside the arena.
Tonic or tonic–clonic convulsive reactions induced by PTZ
(64 mg/kg, ip) served as the motor parameter that was used to
evaluate the effect of the blockade of GABA-mediated Cl– inﬂux.
Seizure latency was deﬁned as the time between injection of PTZ and
the ﬁrst evidence of anterior pawmyoclonia, which was considered to
indicate the beginning of the seizure. The severity of the convulsive
reactionswas evaluated according to the followingmotor paramaters:
index 0=exploratory behavior; index 1=jaw myoclonia and facial
musculature myoclonia, forepaw myoclonia at short duration; index
2=head myoclonia, moderate forepaw at short duration (at least
5 seconds); index 3=forepaw and/or hindpaw severe musculature
hypertonia, forepaw severe musculature hypertonia at intermediate
duration (at least 10 seconds); index 4=forepaw and/or hindpaw
severe musculature hypertonia, rearing, and also forepaw severe
myoclonia; index 5=forepaw and/or hindpaw severe musculature
hypertonia, rearing and falling, and also forepaw severe myoclonia.
PTZ-induced convulsive reactionswere recorded using a video camera
(Panasonic, M3500) focused on the open ﬁeld, and the VHS tapes (JVC,
SX Gold) were subsequently evaluated to classify, characterize, and
quantify the convulsive reactions.
2.5. Neuropharmacological procedures
Five days after surgery, a baseline tail-ﬂick test was performed for
each animal in a given group. Animals in the control group were
removed from the box, placed in the open ﬁeld, and observed for
15 minutes without drug injection. After this period, the animals were
removed from the arena, and their nociceptive thresholds were
standardized using the tail-ﬂick test. After that, an independent group
of animals received microinjections of physiological saline (0.2 or
0.5 μL, n=7 or 8), yohimbine (at 1.0 μg/0.2 μL, n=7, 3.0 μg/0.2 μL,
n=5, 5.0 μg/0.2 μL, n=9, or 5.0 μg/0.5 μL, n=8), propranolol (at
1.0 μg/0.2 μL , n=8, 3.0 μg/0.2 μL, n=7, 5.0 μg/0.2 μL, n=9, or
5.0 μg/0.5 μL, n=8), or norepinephrine (at 1.0 μg/0.2 μL, n=8,
3.0 μg/0.2 μL, n=5, 5.0 μg/0.2 μL, n=6) into the LC. The
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0.3 mm) introduced through the guide cannula until its lower end
extended 1 mm below the guide cannula. The needle was left in place
for an additional 1 minute after the injection. Ten minutes later, the
animals received PTZ (64 mg/kg, ip), and nociceptive responses were
evaluated immediately after the tonic/tonic–clonic seizures and in the
subsequent postictal period from 10 to 180 minutes.
As a control of the eventual intrinsic effect of LC neurons on the
baseline nociceptive thresholds, additional experiments were per-
formed with the following procedures: (1) microinjection of ibotenic
acid (at 1.0 μg/0.2 μL) into the LC followed by intraperitoneal
administration of physiological saline; (2) microinjection of ibotenic
acid (at 1.0 μg/0.2 μL) into the LC followed by intraperitoneal
administration of PTZ; (3) sham procedure (introduction of an
injector needle into the guide cannula inserted in the LC without
local microinjection of the neurotoxin) followed by intraperitoneal
administration of PTZ.
2.6. Drugs
Pentylenetetrazole (Sigma/Aldrich, St. Louis, MO, USA), yohimbine
(Sigma), propranolol (Sigma), norepinephrine (Sigma), and ibotenic
acid (Sigma) were each dissolved in physiological saline (NaCl 0.9%)
shortly before use. Drugs were administered at the following concen-
trations/doses: yohimbine and propranolol (1.0 μg/0.2 μL, 3.0 μg/0.2 μL,
5.0 μg/0.2 μL, or 5.0 μg/0.5 μL); norepinephrine (1.0 μg/0.2 μL,
3.0 μg/0.2 μL, 5.0 μg/0.2 μL); ibotenic acid (1.0 μg/0.2 μL); PTZ
(64 mg/kg).
2.7. Histological analysis
After testing, the rats were anesthetized with sodium pentobar-
bital (45 mg/kg, ip) and perfused via the left ventricle. The blood wasTable 1
Severity of generalized tonic–clonic convulsive reactions induced by intraperitoneal admin
Treatment Latency (s) Du
(A) Animals pretreated with microinjections of physiological saline, yohimbine (5.0 μg
statistically signiﬁcant differences between groups
Saline (NaCl 0.9%) LC+PTZ 111.0 5
Yohimbine 5 μg/0.5 μL LC+PTZ 111.5 4
Propranolol 5 μg/0.5 μL LC+PTZ 108.25 4
(B) Animals pretreated with microinjections of physiological saline or yohimbine (1, 3, o
Saline (NaCl 0.9%) LC+PTZ 72.2 4
Yohimbine 1 μg/0.2 μL LC+PTZ 61.7 8
Yohimbine 3 μg/0.2 μL LC+PTZ 53.1 6
Yohimbine 5 μg/0.2 μL LC+PTZ 77.3 4
(C) Animals pretreated with microinjections of physiological saline, propranolol (1, 3, or
Saline (NaCl 0.9%) LC+PTZ 77 4
Propranolol 1 μg/0.2 μL LC+PTZ 61.3 6
Propranolol 3 μg/0.2 μL LC+PTZ 62.4 8
Propranolol 5 μg/0.2 μL LC+PTZ 57.1 4
(D) Animals pretreated with microinjections of physiological saline or norepinephrine (1
Saline (NaCl 0.9%) LC+PTZ 75.4 4
Norepinephrine 1 μg/0.2 μL LC+PTZ 55.8 6
Norepinephrine 3 μg/0.2 μL LC+PTZ 50.9 9
Norepinephrine 5 μg/0.2 μL LC+PTZ 60.8 11
a See description under Material and Methods.
b Statistically signiﬁcant difference (Pb0.05) compared with the saline-treated group (N
c Statistically signiﬁcant difference (Pb0.05) compared with the group treated with yohim
on repeated-measures ANOVA followed by a Duncan post hoc test.
d Statistically signiﬁcant difference (Pb0.05) compared with the group treated with prop
based on repeated-measures ANOVA followed by a Duncan post hoc test.
e Statistically signiﬁcant difference (Pb0.05) compared with the group treated with norep
based on repeated-measures ANOVA followed by a Duncan post hoc test.washed out with cold, oxygen-enriched, Ca2+-free Tyrode's buffer
(40 mL at 4 °C), followed by 200 mL of ice-cold 4% (w/v) paraformal-
dehyde in 0.1 M sodium phosphate buffer, pH 7.3, for 15 minutes at a
pressure of 50 mm Hg. The brainstem was quickly sectioned,
removed, and immersed in fresh ﬁxative for 4 hours at 4 °C. It was
then rinsed in 10 and 20% sucrose dissolved in 0.1 M sodium
phosphate buffer (pH 7.4) at 4 °C, for at least 12 hours in each
solution. Tissue pieces were immersed in 2-methylbutane (Sigma),
frozen on dry ice, embedded in Tissue Tek OCT, and cut with a cryostat
(HM 505 Microm, Zeiss) at −22 °C. Sections were then mounted on
glass slides coated with chrome alum gelatin to prevent detachment
and stained with hematoxylin–eosin to be viewed on a photomicro-
scope (AxioImager Z1, Zeiss). Statistical analysis was performed
exclusively with data from the animals that presented signs of
microinjections of the drugs into the LC.
2.8. Analysis of results
Data from experiments to investigate the effect of seizures on
nociceptive threshold and the effect of neurotoxic lesions of the LC on
TFLs as well as on postictal antinociception, the involvement of α2-
and β-receptor mediated noradrenergic mechanisms, and the role of
norepinephrine-mediated neurotransmission in postictal antinoci-
ception were submitted to a repeated-measures analysis of variance
(ANOVA). In case of a signiﬁcant treatment versus time interaction,
one-way ANOVA was performed at each time interval, followed by
Duncan's post hoc test. Pb0.05 was indicative of statistically sig-
niﬁcant differences.
3. Results
Wistar rats that had been intraperitoneally administered with PTZ
at 64 mg/kg exhibited distinct types of motor seizures—orofacialistration of PTZ at 64 mg/kg.
ration (s) Seizure frequency Index of severitya
/0.5 μL), or propranolol (5.0 μg/0.5 μL) in the locus coeruleus (LC). There were no
04.0 3.0 4.6
60.0 3.0 4.0
65.0 3.0 4.5
r 5 μg/0.2 μL) in the LC nucleus
55.2 3.0 3.3
35.3b 3.6 3.5
52.5 4.0 3.6
45.5c 3.0 3.4
5 μg/0.2 μL) in the LC nucleus
78.9 3.0 3.4
91.7b 4.12b 3.5
78.b,d 3.14d 3.9
33.2d 3.0d 3.6
, 3, or 5 μg/0.2 μL) in the LC nucleus
74.4 3.0 3.5
85.2 3.3 3.3
84.3b,e 3.2 3.8
43.3b,e 3.6 3.6
aCl 0.9%, n=6).
bine 1 μg/0.2 μL in the LC followed by intraperitoneal injection of PTZ at 64 mg/kg, based
ranolol 1 μg/0.2 μL in the LC followed by intraperitoneal injection of PTZ at 64 mg/kg,
inephrine 1 μg/0.2 μL in the LC followed by intraperitoneal injection of PTZ at 64 mg/kg,
Fig. 1. Representative photomicrographs of transverse sections of the pons of Wistar
rats at the level of the LC. (A) The arrow identiﬁes the LC contralateral to the site of
microinjection (B) of physiological saline, norepinephrine, or noradrenergic receptor
antagonists in the LC. The bar in B corresponds to 96 μm in both (A) and (B).
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clonic seizures, and tonic extension—that covered a period of 7.42–
19.05 minutes, in an average of three or four episodes of motor
seizures in control groups. Animals that had tonic or tonic–clonic
seizures over this time did not resist to convulsive reactions and died
(approximately 10% of seizing rats). Convulsions lasted from 72.2 to
111 seconds in control groups and were not preceded by wild
running. Control animals subjected to the tail-ﬂick test and placedFig. 2. Effect of microinjection of yohimbine (at 5.0 μg/0.5 μl) or propranolol (at 5.0 μg/0.5 μ
Data are presented as means±SEM. *Statistically signiﬁcant difference (Pb0.05) compare
comparedwith the group treated with propranolol in the LC followed by intraperitoneal injec
hoc test.in the experimental scenario for 15 minutes without receiving any
type of drug afterward did not display signiﬁcant changes in their
nociceptive threshold, conﬁrming previous reports [8,9]. There were
no statistically signiﬁcant differences in latency [F(2,20)=0.03,
PN0.05]; number of each PTZ-induced seizure [F(2,20) varying from
0.05 to 0.20, PN0.05 in all cases]; total duration of the convulsive
motor response time window [F(2,20)=1.07, PN0.05]; or severity of
seizures [F(2,20) varying from 0.70 to 1.63, PN0.05 in all cases]
between the physiological saline-, yohimbine- and propranolol-
pretreated groups (Table 1A). Fig. 1 is a photomicrograph represent-
ing the sites of microinjection of drugs in the LC.
Antagonism of α2- and β-noradrenergic receptors in the LC and SC
area decreased postictal antinociception. There were signiﬁcant
effects of treatment [F(2,20)=4.95, Pb0.0001] and time [F(9,12)=
19.65, Pb0.0001] and a treatment versus time interaction [F(18,22)=
19.65, Pb0.0001]. Repeated-measures ANOVA showed a signiﬁcant
treatment effect of yohimbine from 20 to 60 minutes [F(2,20) varying
from 6.1445 to 68.3952, Pb0.05]. Duncan's post hoc test (Pb0.05)
showed that blockade of α2-noradrenergic receptors in the LC caused
a statistically signiﬁcant decrease in postictal antinociception from
0 to 60 minutes following convulsions, whereas a β-noradrenergic
antagonist decreased postictal antinociception from 10 to 60 minutes
following PTZ-induced seizure [F(2,20) varying from 13.40 to 68.39,
Pb0.05]. These data are illustrated in Fig. 2. The site of each drug
microinjection was situated in the LC (Fig. 3).
Both treatments were also conducted using a smaller volume of
each solution. There were no statistically signiﬁcant differences in
latency to [F(3,24)=1.72, PN0.05], number of [F(3,24)=2.29,
PN0.05], or severity of [F(3,24)=0.08, PN0.05] seizures, but there
were statistically signiﬁcant differences in duration [F(3,24)=6.27,
Pb0.05] of each PTZ-induced seizure between the physiological
saline- and yohimbine-pretreated groups (Table 1B).
Also, there were no statistically signiﬁcant differences in the la-
tency to [F(3,27)=1.42, PN0.05], or severity of [F(3,27)=0.38,
PN0.05] seizures, but there were statistically signiﬁcant differences
in number [F(3,27)=5.40, Pb0.05] and duration [F(3,27)=10.42,
Pb0.05] of each PTZ-induced seizure between the physiological saline
and propranolol-pretreated groups (Table 1C).
Furthermore, treatment with a nonspeciﬁc agonist was per-
formed. There were no statistically signiﬁcant differences in the
latency to [F(3,23)=2.70, PN0.05], number of [F(3,23)=0.76,
PN0.05], or severity of [F(3,23)=0.27, PN0.05] seizures, but therel) into the LC nucleus/subcoeruleus area (n=8 per group) on postictal antinociception.
d with the saline-treated group (n=8). #Statistically signiﬁcant difference (Pb0.05)
tion of PTZ at 64 mg/kg, based on repeated-measures ANOVA followed by Duncan`s post
Fig. 3. Schematic representation of histologically conﬁrmed sites of microinjections (closed circles) of (A) saline (NaCl 0.9%, 0.5 μL) in the LC followed by intraperitoneal
administration of PTZ at 64 mg/kg; (B) yohimbine at 5.0 μg/0.5 μL in the LC followed by intraperitoneal injection of PTZ at 64 mg/kg ip; (C) propranolol at 5.0 μg/0.5 μL in the LC
followed by intraperitoneal injection of PTZ 64 mg/kg ip, shown on anagrams of Paxinos and Watson's atlas [90].
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P=0.0001] of each PTZ-induced seizure between the physiological
saline- and norepinephrine-pretreated groups (Table 1D).
Pharmacological antagonism ofα2- and β-noradrenergic receptors
restricted to the LC also decreased postictal antinociception. There
were signiﬁcant effects of treatment [F(2,23)=14.02, Pb0.001], time
[F(9,15)=22.55, Pb0.0001] and a treatment versus time interaction
[F(9,27)=4.60, Pb0.0001]. Repeated-measures ANOVA showed that
yohimbine, at the lowest and highest doses, was not able to decrease
postictal antinociception during the ﬁrst 30 minutes following
seizures, but there was a signiﬁcant treatment effect of yohimbine
from 40 to 120 minutes [F(2,23) varying from 10.88 to 14.99,
Pb0.001]. Moreover, repeated-measures ANOVA showed that yohim-
bine at the intermediate dose was able to antagonize postictal
antinociception from 0 to 120 minutes [F(2,23) varying from 2.15 to
14.99, Pb0.001]. Duncan's post hoc test (Pb0.05) showed that
blockade of α2-noradrenergic receptors in the LC caused a statistically
signiﬁcant decrease in postictal antinociception. These data are
illustrated in Fig. 4. All sites studied were situated in the LC (Fig. 5).
In addition, there were signiﬁcant effects of treatment [F(2,273)=
7.50, P=0.001], time [F(9,19)=139,39, Pb0.0001] and a treatment
versus time interaction [F(9,27)=3.69, Pb0.0001]. Repeated-mea-
sures ANOVA showed that propranolol was able to reduce postictal
antinociception from 0 to 60 minutes [F(2,27) varying from 3.60 to
7.18, Pb0.05] following seizures. Duncan's post hoc test (Pb0.05)showed that blockade of β-noradrenergic receptors in the LC caused a
statistically signiﬁcant decrease in postictal antinociception. These
data are illustrated in Fig. 6. All sites studied were situated in the LC
(Fig. 7).
Administration of the nonspeciﬁc agonist norepinephrine in the LC
caused an interesting depressed effect on postictal antinociception.
There were signiﬁcant effects of treatment [F(2,23)=6.48, P=0.02],
time [F(9,15)=24.11, Pb0.0001] and a treatment versus time
interaction [F(9,27)=3.21, Pb0.0001]. Repeated-measures ANOVA
showed that norepinephrine was able to decrease postictal anti-
nociception from 0 to 60 minutes following seizures [F(2,23) varying
from 10.88 to 14.99, Pb0.001]. Moreover, repeated-measures ANOVA
showed that yohimbine at the intermediate dose was able to reduce
postictal antinociception from 0 to 120 minutes [F(2,23) varying from
3.33 to 6.67, Pb0.05]. Duncan's post hoc test (Pb0.05) showed that
norepinephrine on noradrenergic receptors in the LC caused a
statistically signiﬁcant decrease in postictal antinociception. These
data are illustrated in Fig. 8. All sites studied were situated in the LC
(Fig. 9).
These effects were independent of epileptic seizures induced by
blockade of GABA-mediated Cl− inﬂux, given that central adminis-
tration of yohimbine or propranolol at major concentrations
(5.0 μg/0.5 μL) targeted to the LC did not cause any statistically
signiﬁcant effect on the nociceptive threshold (PN0.05 in all cases, as
compared with the control). Thus, both noradrenergic antagonists
Fig. 4. Effect ofmicroinjectionof yohimbine (at 1 μg/0.2 μL,n=7, 3 μg/0.2 μL,n=5, or 5 μg/0.2 μL,n=9) in the LCnucleus onpostictal antinociception.Data are presented asmeans±SEM.
*Statistically signiﬁcant difference (Pb0.05) compared with the group treated with physiological saline (n=6) followed by intraperitoneal injection of PTZ at 64 mg/kg. +Statistically
signiﬁcant difference (Pb0.05) compared with the group treated with 1 μg/0.2 μL yohimbine in the LC followed by intraperitoneal injection of PTZ at 64 mg/kg, §Statistically signiﬁcant
difference (Pb0.05) comparedwith the group treatedwith 5 μg/0.2 μL yohimbine in the LC followed by intraperitoneal injection of PTZ at 64 mg/kg, based on repeated-measures ANOVA
followed by Duncan`s post hoc test.
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These data are illustrated in Fig. 10. Histological conﬁrmation of the
site of the microinjections in the LC and SC area is presented in
Fig. 11.
Neurochemical lesion of the LC with ibotenic acid caused a
decrease in postictal antinociception. There were signiﬁcant effects
of treatment [F(2,19)=124.94; P=0.001], time [F(9,11)=19.97,
Pb0.001] and a treatment versus time interaction [F(9,18)=26.92,
Pb0.001]. Repeated-measures ANOVA showed that the neurochem-
ical lesion was able to reverse postictal antinociception immediately
after seizures and 10 to 90 minutes after seizures [F(2,19) varying
from 42.49 to 156.90, Pb0.0001]. Moreover, it was shown that the LC
neutotoxic lesion alonewas not able to cause any signiﬁcant change in
baseline TFLs. Duncan's post hoc test also showed statistically
signiﬁcant differences between the group pretreated with ibotenic
acid in the LC followed by IP treatment with PTZ, and the group
pretreated with ibotenic acid in the LC followed by IP treatment with
physiological saline immediately after seizures and from 10 to
60 minutes after tonic–clonic convulsions. These data are illustrated
in Fig. 12. The site of each microinjection procedure was situated in
the LC (Fig. 13).
4. Discussion
In the present study, PTZ-induced tonic–clonic seizures were
accompanied by statistically signiﬁcant antinociception. The present
results demonstrate the involvement of LC neurons in the organization
of postictal antinociception, considering that neurochemical lesion of
the LC neurons decreased the elevation of nociceptive thresholds
after tonic–clonic seizures, but not the baseline TFLs. In addition, the
present work provides evidence for a paradoxical involvement of both
presynaptic α2-autoreceptors and postsynaptic β-noradrenergic re-
ceptors in the LC in the mechanism of postictal antinociception. This
is the ﬁrst presentation of evidence regarding the involvement of
noradrenergic receptors in the LC in antinociceptive phenomena
caused by seizures. Interestingly, recent ﬁndings have demonstrated
that α- and β-noradrenergic receptors participate in other kinds of
hypoalgesia [47,48].
Peng et al. [49] showed that microinjections of yohimbine into
the dorsal horn of the spinal cord antagonize the antinociception
induced by electrical stimulation of the PAG. Expression of α2-
noradrenergic receptor mRNA in noradrenergic neurons in a
previous study [50], however, indicated that this receptor subtype
mediates presynaptic autoreceptor function. We expected thatblockade of this noradrenergic receptor in the LC would increase
postictal antinociception, given that the inhibition of adenylyl
cyclase activity, which results in decreased formation of cAMP, is
an important consequence of α2-noradrenergic receptor activation
[51]. The paradoxical effect of α2-noradrenergic receptor blockade
on postictal antinociception could be easily explained by interac-
tions with inhibitory neurons (e.g., using GABA-mediated neuro-
transmission) modulating the activity of LC noradrenergic outputs.
In fact, a previous neuromorphological study showed evidence of the
presence of GABAergic neurons in the LC [52,53], and LC noradren-
ergic neurons are immunoreactive for the α2 and α3 GABAA receptor
subunits [54]. In addition, there is evidence suggesting the existence
of a subpopulation of small GABAergic neurons in the peri-LC
dendritic zone, which provide interneuronal integration for LC
noradrenergic neurons [42]. This could explain the reduction in the
postictal antinociception curve when yohimbine was administered
centrally in a large volume, possibly involving neurons in the peri-LC
dendritic zone.
Interestingly, some β-noradrenergic receptor antagonists have
been shown to have local anesthetic effects [55–57]. Together with
its classic nonselective β-noradrenergic receptor antagonist effect,
it has been accepted that propranolol inhibits high-voltage ac-
tivated Ca2+ currents and a low-voltage activated Ca2+ current
[58,59] at low concentrations and moderately suppresses potassi-
um currents at high concentrations [60]. In the present study, we
can consider the effects of propranolol on LC neurons to be due to
β-noradrenergic receptor antagonism, given that there was no
intrinsic effect of central pretreatment with propranolol on baseline
TFLs.
Surprisingly, pretreatment of the LC with norepinephrine also
decreased postictal antinociception, suggesting a paradoxical
effect of norepinephrine-mediated neurotransmission into the LC on
antinociceptive outputs from this nucleus. The LC can modulate pain
through classic noradrenergic descending pathways [25,61], but its
inﬂuence on nociceptive stimuli perception can be processed through
an ascending pathway connecting somatosensorial and parafascicular
thalamic nuclei [62,63]. Ascending projections from the LC exert a
dual role at the medial thalamus, acting on parafascicular nucleus
with both facilitatory and inhibitory mechanisms through, respec-
tively, α1- and α2-noradrenergic receptors [63].
Interestingly, Zhang et al. [64] showed that depending on the
dose, administration of norepinephrine in the neostriatum is
followed by either antinociception (at lower doses) or pronocicep-
tion (at higher doses). Another possible explication for these
Fig. 5. Schematic representation of histologically conﬁrmed sites of microinjections
(closed circles) of (A) saline (NaCl 0.9%, 0.5 μL) into the LC followed by intraperitoneal
administration of PTZ at 64 mg/kg; (B) yohimbine 1.0 μg/0.2 μL into the LC followed by
intraperitoneal injection of PTZ at 64 mg/kg; (C) yohimbine 3.0 μg/0.2 μL into the LC
followed by intraperitoneal injection of PTZ at 64 mg/kg; (D) yohimbine 5.0 μg/0.2 μL
into the LC followed by intraperitoneal injection of PTZ at 64 mg/kg, depicted on
anagrams of Paxinos and Watson's atlas [90].
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presynapticα2-noradrenergic receptors, or even on postsynapticα1-
noradrenergic receptors, already implicated in facilitatory mecha-
nisms of pain [65].
In addition, there is other evidence suggesting that the effect of
norepinephrine on noradrenergic receptors can effectively either
facilitate or inhibit nociceptive reﬂexes. Several behavioral in vivo
studies showed that microinjection of an α2-noradrenergic receptor
agonist or an α1-noradrenergic receptor antagonist in the nucleus
raphe magnus causes spinal antinociceptive effects, whereas in-
jections of α1- or α2-noradrenergic receptors agonists cause hyper-
algesic effects [66]. It is known that the action of norepinephrine on
α2-noradrenergic presynaptic receptors decreases about 90% of itsown continuous release on noradrenergic synapses, promoting
negative feedback. The α2-noradrenergic receptor agonist clonidine,
at higher doses, inhibits the release of norepinephrine through the
same negative feedback mechanism in the dorsal horn of the spinal
cord [67]. In addition, according to Green et al. [68], under normal
conditions, the noradrenergic inhibitory feedback system can be
nonresponsive, whereas under pathophysiological conditions it is
commonly active. In a peripheral neuritis experimental model, in-
jection of norepinephrine worsened the mechanical hyperalgesia, and
this was attenuated not only by an α2-noradrenergic receptor antag-
onist, but also by an α1-noradrenergic receptor antagonist [69,70]. In
addition, several studies indicate that the LC is recruited by damaging
nociceptive stimuli, inﬂammation, or nerve lesion by promoting
inhibitory feedback of pain [71,72]. However, although there are
studies showing the involvement of α2-noradrenergic receptors in
norepinephrine-induced pain, there is also behavioral and neuro-
physiological evidence suggesting the involvement of α1-noradren-
ergic receptors in the facilitation of pain [70]. These ﬁndings suggest a
role for LC (direct or indirectly via other structures of the brainstem)
in the facilitation of pain in distinct pathophysiological processes,
such as neuropathic pain [73] or postischemic chronic pain [74]. In
humans, injection of norepinephrine into the tegument was found to
cause hyperalgesia to heat [75].
Supraspinally, the norepinephrine effect on noradrenergic
receptors can both facilitate and inhibit pain depending on the
supraspinal site of its release, the type of receptor subfamily
activated, and the intensity and duration of painful stimuli [70]. In
line with this evidence, it has been postulated that α2-noradren-
ergic receptors situated on noradrenergic neurons (autoreceptors)
cause pronociception, whereas these same receptors situated on
non-noradrenergic neurons (heteroreceptors) cause antinocicep-
tion [70].
We cannot, however, rule out the possibility of involvement of
other mechanisms in the elaboration of postictal antinociception.
In fact, endogenous opioid peptide-, acetylcholine-, serotonin-,
and norepinephrine-mediated systems have been implicated in
the organization of tonic–clonic seizure-induced antinociception
[9,76–78].
Yohimbine microinjected (at lower concentration) into the LC has
also increased the duration of convulsive reactions, but this pretreat-
ment did not modify the severity index of seizures. Intra-LC pre-
treatment with propranolol at the lower concentration caused an
effect similar to that of yohimbine: increasing the duration of con-
vulsive reactions, but exerting no effect on the severity of convulsive
seizures. There is evidence in the literature that both yohimbine and
propranolol modulate convulsive activity [79]. In the present work
norepinephrine, at peak concentrations, increased the duration of
PTZ-induced seizures as evidenced by noradrenergic antagonists such
as yohimbine and propranolol.
Interestingly, it seems that norepinephrine has a dual effect on
convulsive responses, modulating or mediating the elaboration of this
motor phenomenon [79]. In addition to its role in the elaboration/
modulation of postictal antinociception, it is possible that norepi-
nephrine also exerts some effect through α1-noradrenergic receptors
in the elaboration of convulsive responses.
Despite the evidence that the monoaminergic system is crucial to
convulsive reactions [80–85], the LC is considered to be a key struc-
ture involved in the modulation of brain epileptic activity [20,86],
and bilateral lesions of the LC facilitate audiogenic seizures [87].
These data may indicate that the LC exerts a relevant role in postictal
antinociceptive responses. Indeed, recent reports suggest that LC
neurons play an important role in determining immediate early gene
expression, even under conditions of strong pathological activation
such as limbic status epilepticus [88,89], and that neurochemical
lesion of the LC decreases postictal analgesia [9]. The present work
corroborates these ﬁndings and, further, suggests involvement of the
Fig. 6. Effect of microinjections of propranolol (1 μg/0.2 μL, n=8, 3 μg/0.2 μL, n=7, or 5 μg/0.2 μL, n=9) into the LC nucleus on postictal antinociception. Data are presented as
means±SEM. *Statistically signiﬁcant difference (Pb0.05) compared with the group treated with physiological saline (n=7) followed by intraperitoneal injection of PTZ at
64 mg/kg. +Statistically signiﬁcant difference (Pb0.05) compared with the group treated with 1 μg/0.2 μL propranolol into the LC followed by intraperitoneal injection of PTZ at
64 mg/kg. #Statistically signiﬁcant difference (Pb0.05) compared with the group treated with 3 μg/0.2 μL propranolol into the LC followed by intraperitoneal injection of PTZ at
64 mg/kg, based on repeated-measures ANOVA followed by Duncan`s post hoc test.
Fig. 7. Schematic representation of histologically conﬁrmed sites of microinjections (closed circles) of (A) saline (NaCl 0.9%, 0.5 μL) into the LC followed by intraperitoneal
administration of PTZ at 64 mg/kg; (B) propranolol at 1.0 μg/0.2 μL in the LC followed by intraperitoneal administration of PTZ at 64 mg/kg; (C) propranolol at 3.0 μg/0.2 μL into the
LC followed by intraperitoneal administration of PTZ at 64 mg/kg; (D) propranolol at 5.0 μg/0.2 μL into the LC followed by intraperitoneal administration of PTZ at 64 mg/kg, depicted
on anagrams of Paxinos and Watson's atlas [90].
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Fig. 8.Microinjections of yohimbine (5.0 μg/0.5 μl) or propranolol (5.0 μg/0.5 μl) into the LC (n=8) followed by intraperitoneal saline (0.9% NaCl) had no effects on the nociceptive
threshold. Data are presented as means±SEM. PN0.05 in all cases compared with the control group.
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antinociception.
In summary, a decrease in LC activity impairs postictal antinoci-
ception. Antagonism of the increased nociceptive threshold caused
by seizures in all postictal periods was attenuated either by the
direction/indirect action of norepinephrine or by the blockade of α2−
or β-noradrenergic receptors in LC neurons prior to tonic–clonic
seizure-induced analgesia, strongly supporting a role for the involve-Fig. 9. Schematic representation of histologically conﬁrmed sites of microinjections (closed
physiological saline; (B) yohimbine at 5.0 μg/0.5 μL into the LC followed by intraperitoneal ad
by intraperitoneal administration of physiological saline, depicted on anagrams of Paxinosment of noradrenergic pathways and α2- and β-noradrenaline-
mediated LC mechanisms in the organization and modulation of
postictal antinociception.
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